Transparency Market

Research
Liver Diseases Therapeutics
Market - Global Industry Analysis,
Size, Share, And Trends 2!2 -
2!"
Single User License:
USD 4795
Multi User License:
USD 7795
Corporate User License:
USD 10795
Global liver diseases therapeutics #arket e$pected to reach %SD
!&' billion by 2!"( Transparency Market )esearch
Transparency Market Research
State To*er,
', State Street, Suite +&
Albany, ,- !22+
%nited States
***&transparency#arketresearch&co#
sales.transparency#arketresearch&co#
112 Page Report
Publise! Date
1"#$an#201%
&u' (o)
Re*uest Sa+ple
Press Release
Liver Diseases Therapeutics
Market
Li,er Diseases -erapeutics Mar.et # /lobal 0n!ustr' 1nal'sis2 Si3e2 Sare2 1n! -ren!s
2012 # 2014
According a market report published by Transparency Market Research, U.S.based market intelligence
!rm, the "orld"ide market #or liver diseases therapeutics "as estimated to be "orth USD $.% billion in
&'((, and "ill reach USD ('.) billion in &'(*, at a +A,R o# *.$- bet"een &'(& and &'(*. The report,
.Liver Diseases Therapeutics Market /+hemotherapy, Anti0irals, 0accines, Targeted Therapy and
1mmunosuppressants2 ,lobal 1ndustry Analysis, Si3e, Share, Trends And 4orecast &'(& 5 &'(*6 states that
among the entire drug class as covered in the report, antiviral drugs are e7pected to lead the industry by
&'(* as #ar as revenue generation is concerned. The antiviral segment "ill account #or 8&.9- o# the total
market share, #ollo"ed by vaccines "ith ().(- in &'(*.
-o bro)se troug te -oC or purcase te li,er !iseases terapeutics +ar.et report2 ,isit:
ttp:55)))6transparenc'+ar.etresearc6co+5li,er#!iseases#terapeutics6t+l
The ma:or gro"th drivers o# the global liver diseases therapeutics markets highlighted in the TMR report
are "idespread prevalence o# liver diseases, rising geriatric population, a high level o# unmet re;uirements
in liver cancer and rise in vaccination in emerging nations. The report also identi!es some opportunities
that may prove bene!cial to the market in #uture. These include emerging markets in developing countries
such as those in Asia, <astern <urope and Latin America, a number o# strong and highlye=ective drugs in
the pipeline and integrated opportunities in the overall healthcare industry. >o"ever, the study also thro"s
light on those #actors that risk the gro"th o# the market. The sidee=ects and risks o# the drugs, stringent
4DA approvals and government regulations, and the availability o# substitute intervention procedures are
some o# the restraints o# the "orld"ide liver diseases therapeutics market.
The !ve main types o# liver diseases and therapy options as mentioned in the report are autoimmune liver
disorder, nonalcoholic #atty liver disease, alcohol induced liver disease, hepatocellular carcinoma, and
viral?hepatitis liver disorder. The report segments the liver diseases therapeutics industry on the basis o#
drug class into@
Transparency Market )esearch
&
R7P8R- D7SCR0P-08(
Liver Diseases Therapeutics
Market
+hemotherapy drugs
1mmunosuppressants
0accines
Targeted therapy drugs
Antiviral drugs
+orticosteroids
1mmunoglobulins
/et Sa+ple Report Cop' 9ro+ ere :
ttp:55)))6transparenc'+ar.etresearc6co+5sa+ple5sa+ple6pp:;ag<S=rep>i!<799
An the basis o# region, the market is segmented into @
Borth America
<urope
AsiaCaci!c
Rest o# the Dorld.
The report has an e7tensive section on the competitive landscape o# the market and some o# the
companies pro!led in the study are Bovartis, C!3er, Astellas Charma 1nc., Abbot Laboratories, Merck E +o.,
,ilead Science 1nc., Roche, and FristolMyers S;uibb.
More par+aceutical Mar.et Researc Reports at :
ttp:55)))6transparenc'+ar.etresearc6co+5par+aceutical#+ar.et#reports#16t+l
C?1P-7R 1 PR791C7
(.( R<CART D<S+R1CT1AB
(.& R<S<AR+> M<T>ADALA,G
Transparency Market )esearch
8
-1&L7 89 C8(-7(-
Liver Diseases Therapeutics
Market
C?1P-7R 2 7@7CU-0A7 SUMM1RB
C?1P-7R % M1RC7- 8A7RA07D
8.( 1BTRADU+T1AB
8.& MARH<T S1I<
8.8 +AMCARAT10< ABALGS1S A4 ,LAFAL L10<R D1S<AS<S T><RAC<UT1+S MARH<T, FG DRU, +LASS, &'(( E
&'(*
8.J L10<R D1S<AS<S T><RAC<UT1+S MARH<T DGBAM1+S
8.J.( DR10<RS
8.J.(.( Aging population inducing chronic liver diseases such as hepatitis and liver cancer
8.J.(.& 1ncreasing global prevalence o# liver diseases
8.J.(.8 >igh unmet needs e7ist in the liver cancer therapeutics
8.J.(.J 1ncreased vaccination in emerging economies
8.J.& L10<R D1S<AS< T><RAC<UT1+S MARH<T DR10<RS 1MCA+T ABALGS1S
8.J.8 R<STRA1BTS
8.J.8.( Sidee=ects and risks
8.J.8.& 4DA approvals and other government regulations
8.J.8.8 Availability o# alternate treatment procedures
8.J.J L10<R D1S<AS< T><RAC<UT1+S MARH<T R<STRA1BTS 1MCA+T ABALGS1S
8.J.% ACCARTUB1T1<S
Transparency Market )esearch
J
Liver Diseases Therapeutics
Market
8.J.%.( Strong pipeline drugs
8.J.%.& <merging economies in Asia, Latin America and <astern <uropean countries
8.J.%.8 +onsolidation opportunities in the healthcare industry
8.% CART<RKS 410< 4AR+<S ABALGS1S 4AR L10<R D1S<AS<S T><RAC<UT1+S MARH<T
8.%.( FAR,A1B1B, CAD<R A4 SUCCL1<RS
8.%.& FAR,A1B1B, CAD<R A4 FUG<RS
8.%.8 T>R<AT A4 B<D <BTRABTS
8.%.J T>R<AT A4 SUFST1TUT<S
8.%.% +AMC<T1T10< R10ALRG
C?1P-7R 4 L0A7R D0S71S7S CL1SS090C1-08( 1(D -?7R1PB 8P-08(S
J.( AL+A>AL 1BDU+<D L10<R D1S<AS<
J.(.( A0<R01<D
J.(.& <C1D<M1ALA,G
J.(.8 <T1ALA,G
J.(.J SGMCTAMS
J.(.% CAT>AC>GS1ALA,G
J.(.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.(.$.( Anabolic Steroids
J.(.$.& Alcohol Abuse Drugs
J.& AUTA1MMUB< L10<R D1SARD<R
Transparency Market )esearch
%
Liver Diseases Therapeutics
Market
J.&.( AUTA1MMUB< ><CAT1T1S /A1>2
J.&.(.( A0<R01<D
J.&.(.& <C1D<M1ALA,G
J.&.(.8 <T1ALA,G
J.&.(.J SGMCTAMS
J.&.(.% CAT>AC>GS1ALA,G
J.&.(.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.&.(.$.( Antimetabolites
J.&.(.$.& +orticosteroids
J.8 ><CATA+<LLULAR +AR+1BAMA
J.8.( A0<R01<D
J.8.& <C1D<M1ALA,G
J.8.8 <T1ALA,G
J.8.J SGMCTAMS
J.8.% CAT>AC>GS1ALA,G
J.8.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.8.$.( +hemotherapy
J.8.$.& Targeted Therapy
J.J BABAL+A>AL1+ 4ATTG L10<R D1S<AS<
J.J.( A0<R01<D
J.J.& <C1D<M1ALA,G
Transparency Market )esearch
$
Liver Diseases Therapeutics
Market
J.J.8 <T1ALA,G
J.J.J SGMCTAMS
J.J.% CAT>AC>GS1ALA,G
J.J.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.J.$.( ,allstone solubilising drugs
J.% 01RAL?><CAT1T1S L10<R D1SARD<R
J.%.( ><CAT1T1S A
J.%.(.( A0<R01<D
J.%.(.& <C1D<M1ALA,G
J.%.(.8 <T1ALA,G
J.%.(.J SGMCTAMS
J.%.(.% CAT>AC>GS1ALA,G
J.%.(.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.%.(.$.( 0accines
J.%.(.$.& 1mmunoglobulins
J.%.& ><CAT1T1S F
J.%.&.( A0<R01<D
J.%.&.& <C1D<M1ALA,G
J.%.&.8 <T1ALA,G
J.%.&.J SGMCTAMS
J.%.&.% CAT>AC>GS1ALA,G
Transparency Market )esearch
9
Liver Diseases Therapeutics
Market
J.%.&.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.%.&.$.( Antiviral drugs
J.%.&.$.& 1mmunoglobulins
J.%.&.$.8 0accines
J.%.8 ><CAT1T1S +
J.%.8.( A0<R01<D
J.%.8.& <C1D<M1ALA,G
J.%.8.8 <T1ALA,G
J.%.8.J SGMCTAMS
J.%.8.% CAT>AC>GS1ALA,G
J.%.8.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.%.8.$.( Antiviral drugs
J.%.J ><CAT1T1S D
J.%.J.( A0<R01<D
J.%.J.& <C1D<M1ALA,G
J.%.J.8 <T1ALA,G
J.%.J.J SGMCTAMS
J.%.J.% CAT>AC>GS1ALA,G
J.%.J.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
J.%.% ><CAT1T1S <
J.%.%.( A0<R01<D
Transparency Market )esearch
*
Liver Diseases Therapeutics
Market
J.%.%.& <C1D<M1ALA,G
J.%.%.8 <T1ALA,G
J.%.%.J SGMCTAMS
J.%.%.% CAT>AC>GS1ALA,G
J.%.%.$ TR<ATM<BT CATT<RB ABD T><RACG ACT1ABS
C?1P-7R 5 L0A7R D0S71S7S -?7R1P7U-0CS M1RC7-2 &B DRU/ CL1SS
%.( 1MMUBASUCCR<SSABTS
%.(.( ,LAFAL 1MMUBASUCCR<SSABTS MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(*
/USD M1LL1AB2
%.& +><MAT><RACG DRU,S
%.&.( ,LAFAL +><MAT><RACG DRU,S MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(* /USD
M1LL1AB2
%.8 TAR,<T<D T><RACG DRU,S
%.8.( ,LAFAL TAR,<T<D T><RACG MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(* /USD
M1LL1AB2
%.J 0A++1B<S
%.J.( ,LAFAL 0A++1B<S MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(* /USD M1LL1AB2
%.% ABT101RAL DRU,S
%.%.( ,LAFAL ABT101RAL DRU,S MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(* /USD
M1LL1AB2
%.$ 1MMUBA,LAFUL1BS
Transparency Market )esearch
)
Liver Diseases Therapeutics
Market
%.$.( ,LAFAL 1MMUBA,LAFUL1BS MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(* /USD
M1LL1AB2
%.9 +ART1+AST<R1ADS
%.9.( ,LAFAL +ART1+AST<R1ADS MARH<T 4AR L10<R D1S<AS< T><RAC<UT1+S, &'(' 5 &'(* /USD
M1LL1AB2
Relate! Mar.et Researc Reports :
9acial Care Mar.et in 1sia#PaciEc:
ttps:55)))6lin.e!in6co+5to!a'5post5article52014040"0"5914#%44022451#Facial#care#+ar.et#
in#asia#paciEc#is#)ort#us!#%9#75#billion#globall'#b'#2019#transparenc'#+ar.et#researc
/lobal Car Rental Mar.et :
ttps:55)))6lin.e!in6co+5to!a'5post5article52014040"12004%#%44022451#global#car#rental#
+ar.et#is#)ort#us!#79#4"#billion#b'#2019#transparenc'#+ar.et#researc
C?1P-7R " C8MP7-0-0A7 L1(DSC1P7
$.( MARH<T S>AR< A4 H<G CLAG<RS 1B L10<R D1S<AS<S T><RAC<UT1+S MARH<T FG DRU, +LASS
$.(.( MARH<T S>AR< A4 H<G CLAG<RS 4AR 1MMUBASUCCR<SSABTS MARH<T 4AR L10<R D1S<AS<S
$.(.& MARH<T S>AR< A4 H<G CLAG<RS 4AR 0A++1B<S MARH<T 4AR L10<R D1S<AS<S
$.(.8 MARH<T S>AR< A4 H<G CLAG<RS 4AR ABT101RAL DRU,S MARH<T 4AR L10<R D1S<AS<S
$.(.J MARH<T S>AR< A4 H<G CLAG<RS 4AR TAR,<T<D T><RACG 4AR L10<R D1S<AS<S
$.(.% B<D <BTRABTS /C>AS< 1112
$.(.$ +AMC<T1T10< STRAT<,G FG H<G CLAG<RS
$.(.$.( 1nvestments in RED and clinical studies
$.(.$.& <ntering the emerging economies
$.(.$.8 1nvesting in di=erent segments o# the market
Transparency Market )esearch
('
Liver Diseases Therapeutics
Market
$.(.9 +AMC<T1T10< STRAT<,G FG B<D <BTRABTS
$.(.* A,R<<M<BTS ABD +ALLAFARAT1ABS
C?1P-7R 7 R7C8MM7(D1-08(S
9.( MARH<T STRAT<,G 4AR SU++<SS
9.& FARR1<RS TA F< +ABS1D<R<D
C?1P-7R 4 C8MP1(B PR890L7S
*.( AFFATT LAFARATAR1<S
*.(.( +AMCABG A0<R01<D
*.(.& 41BAB+1AL A0<R01<D
*.(.8 FUS1B<SS STRAT<,1<S
*.(.8.( Signi!cant RED investments #or ne" products development
*.(.8.& 1nvesting in emerging markets
*.(.8.8 +onducting clinical trials
*.(.J CRADU+T CART4AL1A
*.(.% R<+<BT D<0<LACM<BTS
*.& AST<LLAS C>ARMA 1B+.
*.&.( +AMCABG A0<R01<D
*.&.& 41BAB+1AL A0<R01<D
*.&.8 FUS1B<SS STRAT<,1<S
Transparency Market )esearch
((
Liver Diseases Therapeutics
Market
*.&.8.( 1nvesting in emerging economies
*.&.8.& 1nvesting in research and development
*.&.J CRADU+T CART4AL1A
*.&.% R<+<BT D<0<LACM<BTS
*.8 FR1STALMG<RS SLU1FF
*.8.( +AMCABG A0<R01<D
*.8.& 41BAB+1AL A0<R01<D
*.8.8 FUS1B<SS STRAT<,1<S
*.8.8.( Mergers, ac;uisitiosn and strategic development
*.8.8.& 1nvesting in research and development
*.8.J CRADU+T CART4AL1A
*.8.% R<+<BT D<0<LACM<BTS
*.J ,1L<AD S+1<B+<S
*.J.( +AMCABG A0<R01<D
*.J.& 41BAB+1AL A0<R01<D
*.J.8 FUS1B<SS STRAT<,1<S
*.J.8.( 1nnovative ne" products
*.J.8.& 1nvesting in research and development
*.J.J CRADU+T CART4AL1A
*.J.% R<+<BT D<0<LACM<BTS
*.% ,LAMASM1T>HL1B< CL+
Transparency Market )esearch
(&
Liver Diseases Therapeutics
Market
*.%.( +AMCABG A0<R01<D
*.%.& 41BAB+1AL A0<R01<D
*.%.8 FUS1B<SS STRAT<,1<S
*.%.8.( Research and development investments
*.%.8.& Delivering ne" products
*.%.J CRADU+T CART4AL1A
*.%.% R<+<BT D<0<LACM<BTS
*.$ 4. >A44MABBLA RA+>< LTD
*.$.( +AMCABG A0<R01<D
*.$.& 41BAB+1AL A0<R01<D
*.$.8 FUS1B<SS STRAT<,1<S
*.$.8.( Strategic alliance initiative
*.$.8.& 1nvesting in research and development
*.$.J CRADU+T CART4AL1A
*.$.% R<+<BT D<0<LACM<BTS
*.9 M<R+H E +A. 1B+
*.9.( +AMCABG A0<R01<D
*.9.& 41BAB+1AL A0<R01<D
*.9.8 FUS1B<SS STRAT<,1<S
*.9.8.( RED initiatives
*.9.8.& Strategic alliance
Transparency Market )esearch
(8
Liver Diseases Therapeutics
Market
*.9.8.8 +orporate social responsibility and a"areness
*.9.J CRADU+T CART4AL1A
*.9.% R<+<BT D<0<LACM<BTS
*.* BA0ART1S A,
*.*.( +AMCABG A0<R01<D
*.*.& 41BAB+1AL A0<R01<D
*.*.8 FUS1B<SS STRAT<,1<S
*.*.8.( Strategic alliance
*.*.8.& 1nvesting in research and development
*.*.J CRADU+T CART4AL1A
*.*.% R<+<BT D<0<LACM<BTS
*.) SABA41 S.A
*.).( +AMCABG A0<R01<D
*.).& 41BAB+1AL A0<R01<D
*.).8 FUS1B<SS STRAT<,1<S
*.).8.( Fusiness Diversi!cation
*.).8.& Research and development initiative
*.).J CRADU+T CART4AL1A
*.).% R<+<BT D<0<LACM<BTS
*.(' C41I<R 1B+.
*.('.( +AMCABG A0<R01<D
Transparency Market )esearch
(J
Liver Diseases Therapeutics
Market
*.('.& 41BAB+1AL A0<R01<D
*.('.8 FUS1B<SS STRAT<,1<S
*.('.8.( 1nvesting in research and development
*.('.J CRADU+T CART4AL1A
*.('.% R<+<BT D<0<LACM<BTS
*.(( TAH<DA C>ARMA+<UT1+AL
*.((.( +AMCABG A0<R01<D
*.((.& 41BAB+1AL A0<R01<D
*.((.8 FUS1B<SS STRAT<,1<S
*.((.8.( 1nvesting in emerging economies
*.((.8.& 1nvesting in research and development
*.((.J CRADU+T CART4AL1A
*.((.% R<+<BT D<0<LACM<BTS
*.(& 0AL<ABT C>ARMA+<UT1+ALS
*.(&.( +AMCABG A0<R01<D
*.(&.& 41BAB+1AL A0<R01<D
*.(&.8 FUS1B<SS STRAT<,1<S
*.(&.8.( Strategic alliance
*.(&.J CRADU+T CART4AL1A
*.(&.% R<+<BT D<0<LACM<BTS
*.(8 DATSAB C>ARMA+<UT1+ALS, 1B+.
Transparency Market )esearch
(%
Liver Diseases Therapeutics
Market
*.(8.( +AMCABG A0<R01<D
*.(8.& 41BAB+1AL A0<R01<D
*.(8.8 FUS1B<SS STRAT<,1<S
*.(8.8.( 1nvesting in generic and biosimilar segments
*.(8.8.& 1nvesting in research and development
*.(8.J CRADU+T CART4AL1A
*.(8.% R<+<BT D<0<LACM<BTS
&ro)se 9ull Report Dit -8C :
ttp:55)))6transparenc'+ar.etresearc6co+5li,er#!iseases#terapeutics6t+l
Transparency Market )esearch
($
Liver Diseases Therapeutics
Market
Transparency Market Research is a market intelligence company providing global business in#ormation
reports and services. Aur e7clusive blend o# ;uantitative #orecasting and trends analysis provides #or"ard
looking insight #or thousands o# decision makers.
De are privileged "ith highly e7perienced team o# Analysts, Researchers and +onsultants, "ho use
proprietary data sources and various tools and techni;ues to gather, and analy3e in#ormation. Aur
business o=erings represent the latest and the most reliable in#ormation indispensable #or businesses to
sustain a competitive edge.
Contact:
Transparency Market Research
)' State Street,
Suite 9'',
Albany
BG (&&'9
United States
Tel@ N(%(*$(*('8'
USA +anada Toll 4ree *$$%%&8J%8
<mail@ salesOtransparencymarketresearch.com
Debsite@ http@??""".transparencymarketresearch.com?
Transparency Market )esearch
(9
1bout Us